SCHEMBL2706374

SCHEMBL2706374

NS(=O)(=O)c1ccc(Nc2nc(-c3ccc(O)cc3O)cs2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 1.00
MEN1 O00255 5/20 1.00
KMT2A Q03164 5/20 1.00
VCP P55072 2/20 1.00
KDM4E B2RXH2 2/20 1.00
POLB P06746 1/20 1.00
GAA P10253 1/20 1.00
HPGD P15428 1/20 1.00
GFER P55789 1/20 1.00
AMY1A P0DUB6 5/20 0.76
SMN1; SMN2 Q16637 3/20 0.74
MAPK1 P28482 2/20 0.74
TP53 P04637 1/20 0.74
THRB P10828 1/20 0.74
ALOX15 P16050 1/20 0.74
HSD17B10 Q99714 1/20 0.74
TYR P14679 2/20 0.69
CSNK2A1 P68400 1/20 0.69
HTT P42858 1/20 0.61
RAB9A P51151 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL205697 0.92 MEN1 (0.84) MAPTMEN1KMT2AVCPKDM4E
SCHEMBL12295951 0.82 AMY1A (0.84) MAPTMEN1KMT2AVCPKDM4E
SCHEMBL2703774 0.81 AMY1A (1.00) MAPTMEN1KMT2AVCPKDM4E
SCHEMBL11888656 0.81 MAPT (0.78) MAPTMEN1KMT2AVCPKDM4E
SCHEMBL22680216 0.80 MAPT (0.87) MAPTMEN1KMT2AVCPKDM4E
SCHEMBL18543638 0.80 TYR (1.00) MAPTMEN1KMT2AVCPKDM4E
SCHEMBL12297546 0.79 VCP (1.00) MAPTMEN1KMT2AVCPKDM4E
SCHEMBL29740077 0.79 MEN1 (0.70) MAPTMEN1KMT2AVCPKDM4E
SCHEMBL22680400 0.77 MAPT (0.79) MAPTMEN1KMT2AVCPKDM4E
SCHEMBL22680557 0.77 MEN1 (0.97) MAPTMEN1KMT2AVCPKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE PIGS, CPT1A, SLC10A1 MAPT 2207/4885MEN1 3862/4885KMT2A 3476/4885
US-20070004711-A1 Thiazole compounds and methods of use PIGS, CPT1A, SLC10A1 MAPT 2207/4885MEN1 3862/4885KMT2A 3476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.